DEVELOPMENTAL CANCER THERAPEUTICS

$43,055P30FY2017CANIH

Medical University Of South Carolina, Charleston SC

Investigators

Linked publications & trials

Paper 39716322 Paper 39561045 Paper 39554796 Paper 39391533 Paper 39379700 Paper 39347566 Paper 39312723 Paper 39292167 Paper 39264252 Paper 39225558 Paper 39146811 Paper 39108242 Paper 39046874 Paper 39037017 Paper 39000384 Paper 38980715 Paper 38945552 Paper 38885332 Paper 38856163 Paper 38853930 Paper 38853284 Paper 38824916 Paper 38802657 Paper 38779482 Paper 38752949 Paper 38709899 Paper 38681116 Paper 38668812 Paper 38632569 Paper 38617240 Paper 38570770 Paper 38570462 Paper 38546787 Paper 38546445 Paper 38515274 Paper 38509768 Paper 38464312 Paper 38417823 Paper 38381042 Paper 38373106 Paper 38365772 Paper 38364938 Paper 38352443 Paper 38329320 Paper 38329128 Paper 38319231 Paper 38273829 Paper 38255295 Paper 38222066 Paper 38200579 Paper 38194131 Paper 38177192 Paper 38174740 Paper 38164625 Paper 38136410 Paper 38081134 Paper 37977486 Paper 37967292 Paper 37961721 Paper 37942694 Paper 37914699 Paper 37902448 Paper 37828860 Paper 37822942 Paper 37819702 Paper 37806365 Paper 37803429 Paper 37745348 Paper 37745346 Paper 37731255 Paper 37720013 Paper 37609318 Paper 37566040 Paper 37560455 Paper 37481703 Paper 37461579 Paper 37427141 Paper 37399416 Paper 37382737 Paper 37338201 Paper 37333126 Paper 37322469 Paper 37268417 Paper 37211959 Paper 37126482 Paper 37092117 Paper 37081789 Paper 37071464 Paper 36993287 Paper 36913266 Paper 36909595 Paper 36868225 Paper 36864125 Paper 36828843 Paper 36803404 Paper 36749843 Paper 36743586 Paper 36710461 Paper 36657266 Paper 36650050

Abstract

The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: ? Elucidation of Cellular Signaling Pathways. ? Modulation of Redox and Cellular Stress Response. ? Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated; 224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.

View original record on NIH RePORTER →